Vaccinium para Diabetes y control glucémico
Vaccinium arctostaphylos — 12 estudios científicos revisados
Moderate¿Sirve Vaccinium para diabetes y control glucémico?
Uso documentado en la medicina tradicional y respaldado por investigación preliminar
Compuestos activos involucrados: Fenoles, Flavonoides, Glucosa, Polifenoles, Saponinas, Terpenos, Tirosinasa, Compuestos fenólicos
Evidencia Científica
Los siguientes estudios han investigado la relación entre Vaccinium y diabetes y control glucémico:
The Potential Hepatoprotective Effect of
OBJECTIVE: MATERIALS AND METHODS: In this experimental study, male Wistar rats were randomly assigned to four groups: normal control, normal rats with VAE treatment, diabetic control, and diabetic rats with VAE treatment. Following 42 days of treatment, the impact of VAE on diabetes-induced rats was assessed by measuring various serum biochemical parameters, including insulin, free fatty acids (FFA), tumor necrosis factor-α (TNF-α), reactive oxygen species (ROS), and adiponectin levels. The activities of hepatic carbohydrate metabolic enzymes and glycogen content were determined. Additionally
PubMed: 37865880Anti-hyperglycemic effect of Vaccinium arctostaphylos in type 2 diabetic patients: a randomized controlled trial.
BACKGROUND: Type 2 diabetes mellitus is a common disease. Preliminary data indicate that Vaccinium arctostaphylos L. (Caucasian whortleberry) has a potential effect in glycemic control. Thus, the efficacy and safety of a standardized whortleberry fruit hydroalcoholic extract in the treatment of type 2 diabetic patients were studied. METHODS: This randomized double-blind placebo-controlled clinical trial consisted of 37 patients aged 40-60 years with type 2 diabetes who were resistant to conventional oral anti-hyperglycemic drugs.
PubMed: 23727759Bioassay-guided separation of an alpha-amylase inhibitor anthocyanin from Vaccinium arctostaphylos berries.
Vaccinium arctostaphylos is a traditional medicinal plant in Iran used for the treatment of diabetes mellitus. In our search for antidiabetic compounds from natural sources, we found that the extract obtained from V. arctostaphylos berries showed an inhibitory effect on pancreatic alpha-amylase in vitro [IC50 = 1.91 (1.89-1.94) mg/mL]. The activity-guided purification of the extract led to the isolation of malvidin-3-O-beta-glucoside as an a-amylase inhibitor. The compound demonstrated a dose-dependent enzyme inihibitory activity [IC50 = 0.329 (0.316-0.342) mM].
PubMed: 21138057Persian Medicinal Plants as Antidiabetic Agents: Mechanisms and Evidence from Bench to Bedside .
The use of medicinal plants by diabetic patients dates back to ancient times. In recent years, numerous reports have been published on the efficacy and safety of many medicinal plants in the treatment of diabetes through various mechanisms. This review highlights the up-to-date proposed mechanisms of action of the most common antidiabetic herbs used in Persian medicine, comprising Cinnamomum zeylanicum, Trigonella foenum-graecum, Urtica dioica, Nigella sativa, Citrullus colocynthis, Silybum marianum, Zingiber officinale, Punica granatum, Salvia officinalis, Vaccinium arctostaphylos, and Momord
PubMed: 41287595Antihypertensive efficacy and safety of Vaccinium arctostaphylos berry extract in overweight/obese hypertensive patients: A randomized, double-blind and placebo-controlled clinical trial.
OBJECTIVES: To evaluate the antihypertensive efficacy and safety of a standardized Vaccinium arctostaphylos (V. arctostaphylos) berry hydro-alcoholic extract in the overweight/obese hypertensive patients. DESIGN: Randomized placebo-controlled trial. SETTING: Baqiyatallah hospital (Tehran, Iran). INTERVENTIONS: The antihypertensive efficacy and safety of 3-month intake of 400 mg extract capsule three times daily alongside standardized anti-hypertensive regimen in the treatment of 50 patients was compared with the placebo (n = 50).
PubMed: 31126570Seguridad y Precauciones
La seguridad del consumo de Vaccinium arctostaphylos debe abordarse con precaución debido a sus potentes efectos farmacológicos sobre el metabolismo de la glucosa y la presión arterial. En cuanto al embarazo y la lactancia, no existe evidencia clínica suficiente en humanos que garantice la seguridad del uso de extractos concentrados de esta planta en mujeres gestantes o lactantes. Dado que estudios en modelos animales sugieren efectos sobre la expresión génica y el metabolismo (como la regulación de la insulina y el transporte de glucosa), existe un riesgo teórico de interferencia con el desarrollo fetal o la transferencia de compuestos bioactivos a través de la leche materna. La falta de estudios de seguridad en humanos durante estas etapas clínicas obliga a recomendar la abstención de su uso terapéutico en estos grupos vulnerables. Para niños menores de 12 años, el uso de extractos de Vaccinium arctostaphylos no está indicado. El desarrollo fisiológico de los infantes es altamente sensible a cambios en los niveles de glucosa y hormonas; el uso de agentes con propiedades hipoglucemiantes podría provocar episodios de hipoglucemia (niveles bajos de azúcar en sangre) difíciles de manejar en pediatría.
Otras plantas estudiadas para Diabetes y control glucémico
Perfil completo: Ver todos los usos y evidencia de Vaccinium →